Clinical trial
A Single-Arm, Prospective Phase II Clinical Study of Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
NCT07545083 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Arm, Prospective Phase II Clinical Study of Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- April 30, 2026
- Completion date
- August 31, 2029
- Enrollment
- 26 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced oral and oropharyngeal squamous cell carcinoma